Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Mohamed El Kassas, Tamer Elbaz, Enas Hafez, Mohamed Naguib Wifi & Gamal Esmat. (2017) Discovery and preclinical development of dasabuvir for the treatment of hepatitis C infection. Expert Opinion on Drug Discovery 12:6, pages 635-642.
Read now
Read now
Articles from other publishers (20)
Ankush Kumar, Raj Kumar Narang & Rohit Bhatia. (2023) Recent advancements in NS5B inhibitors (2011-2021): Structural insights, SAR studies and clinical status. Journal of Molecular Structure 1293, pages 136272.
Crossref
Crossref
Shikha Kaushik, Sarvesh Kumar Paliwal, Malliga R. Iyer & Vaishali M. Patil. (2023) Promising Schiff bases in antiviral drug design and discovery. Medicinal Chemistry Research 32:6, pages 1063-1076.
Crossref
Crossref
Madeleine I. Ezeh, Onyinyechi E. Okonkwo, Innocent N. Okpoli, Chima E. Orji, Benjamin U. Modozie, Augustine C. Onyema & Fortunatus C. Ezebuo. (2022) Chemoinformatic Design and Profiling of Derivatives of Dasabuvir, Efavirenz, and Tipranavir as Potential Inhibitors of Zika Virus RNA-Dependent RNA Polymerase and Methyltransferase. ACS Omega 7:37, pages 33330-33348.
Crossref
Crossref
Shuang Chen, Yi Gao, Xiaochun Lou, Rodger F. Henry, DeAnne F. Stolarik, Maya P. Lipert, Ahmad Y. Sheikh & Geoff G. Z. Zhang. (2022) Overcoming Bioavailability Challenges of Dasabuvir and Enabling a Triple-Combination Direct-Acting Antiviral HCV Regimen through a Salt of Very Weak Acid for Oral Delivery. Molecular Pharmaceutics 19:7, pages 2367-2379.
Crossref
Crossref
Helga Rübsamen‐Schaeff & Helmut BuschmannMichael J. Sofia. 2022. New Drug Development for Known and Emerging Viruses. New Drug Development for Known and Emerging Viruses
13
57
.
Tsuyoshi Hayashi, Kosuke Murakami, Junki Hirano, Yoshiki Fujii, Yoko Yamaoka, Hirofumi Ohashi, Koichi Watashi, Mary K. Estes & Masamichi Muramatsu. (2021) Dasabuvir Inhibits Human Norovirus Infection in Human Intestinal Enteroids. mSphere 6:6.
Crossref
Crossref
Darshana Bora, Srinivas Reddy Dannarm, Stephy Elza John, Sravani Sana, Rajesh Sonti & Nagula Shankaraiah. (2021)
Regioselective
ortho
‐sulfonamidation: Exploration of Intrinsic Directing Property of β‐Carbolines and their Photophysical Studies
. Asian Journal of Organic Chemistry 10:12, pages 3384-3389.
Crossref
Crossref
Rahul Kumar, Sahil Mishra, Shreya & Sushil K. Maurya. (2021) Recent advances in the discovery of potent RNA-dependent RNA-polymerase (RdRp) inhibitors targeting viruses. RSC Medicinal Chemistry 12:3, pages 306-320.
Crossref
Crossref
Anastasia Khandazhinskaya, Elena Matyugina & Mikhail Novikov. 2021. Coronaviruses and other Novel Antiviral Targets. Coronaviruses and other Novel Antiviral Targets
175
238
.
Michal Stefanik, James J. Valdes, Fortunatus C. Ezebuo, Jan Haviernik, Ikemefuna C. Uzochukwu, Martina Fojtikova, Jiri Salat, Ludek Eyer & Daniel Ruzek. (2020) FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells. Microorganisms 8:4, pages 599.
Crossref
Crossref
Amy Puenpatom, Michael Hull, Jeffrey McPheeters & Kay Schwebke. (2017) Treatment Discontinuation, Adherence, and Real-World Effectiveness Among Patients Treated with Ledipasvir/Sofosbuvir in the United States. Infectious Diseases and Therapy 6:3, pages 423-433.
Crossref
Crossref
Guanghai Jin, Jisu Lee & Kyeong Lee. (2017) Chemical genetics-based development of small molecules targeting hepatitis C virus. Archives of Pharmacal Research 40:9, pages 1021-1036.
Crossref
Crossref
Annina Burhop, Remo Weck, Jens Atzrodt & Volker Derdau. (2017) Hydrogen-Isotope Exchange (HIE) Reactions of Secondary and Tertiary Sulfonamides and Sulfonylureas with Iridium(I) Catalysts. European Journal of Organic Chemistry 2017:11, pages 1418-1424.
Crossref
Crossref
N.A. Meanwell. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
553
627
.
Bianca Heinrich & John P. Bilello. 2017. Antimicrobial Drug Resistance. Antimicrobial Drug Resistance
579
609
.
Martijn Fenaux, Xiaodong Lin, Fumiaki Yokokawa, Zachary Sweeney, Oliver Saunders, Lili Xie, Siew Pheng Lim, Marianne Uteng, Kyoko Uehara, Robert Warne, Wang Gang, Christopher Jones, Satya Yendluri, Helen Gu, Keith Mansfield, Julie Boisclair, Tycho Heimbach, Alexandre Catoire, Kathryn Bracken, Margaret Weaver, Heinz Moser & Weidong Zhong. (2016)
Antiviral Nucleotide Incorporation by Recombinant Human Mitochondrial RNA Polymerase Is Predictive of Increased
In Vivo
Mitochondrial Toxicity Risk
. Antimicrobial Agents and Chemotherapy 60:12, pages 7077-7085.
Crossref
Crossref
Autumn Bagwell & Cody A. Chastain. (2016) Hepatitis C Treatment in HIV Coinfection: Approaches, Challenges, and Future Opportunities. Current Treatment Options in Infectious Diseases 8:4, pages 379-399.
Crossref
Crossref
Emma Hathorn & Ahmed M Elsharkawy. (2016) Management of hepatitis C genotype 4 in the directly acting antivirals era. BMJ Open Gastroenterology 3:1, pages e000112.
Crossref
Crossref
Tutik Sri Wahyuni, Chie Aoki Utsubo & Hak Hotta. (2016) Promising Anti-Hepatitis C Virus Compounds from Natural Resources. Natural Product Communications 11:8, pages 1934578X1601100.
Crossref
Crossref
John J. Court, Carl Poisson, Andrzej Ardzinski, Darius Bilimoria, Laval Chan, Kishan Chandupatla, Nathalie Chauret, Philip N. Collier, Sanjoy Kumar Das, Francois Denis, Warren Dorsch, Ganesh Iyer, David Lauffer, Lucille L’Heureux, Pan Li, Brian S. Luisi, Nagraj Mani, Suganthi Nanthakumar, Olivier Nicolas, B. Govinda Rao, Steven Ronkin, Subajini Selliah, Rebecca S. Shawgo, Qing Tang, Nathan D. Waal, Constantin G. Yannopoulos & Jeremy Green. (2016) Discovery of Novel Thiophene-Based, Thumb Pocket 2 Allosteric Inhibitors of the Hepatitis C NS5B Polymerase with Improved Potency and Physicochemical Profiles. Journal of Medicinal Chemistry 59:13, pages 6293-6302.
Crossref
Crossref